title: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
abstract: Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.
authors.affiliation: University of Pennsylvania Medical Center, Philadelphia, 19104, USA. david.porter@uphs.upenn.edu
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
authors.forename: Marcos
authors.initials: M
authors.lastname: DeLima
authors.forename: Eli
authors.initials: E
authors.lastname: Estey
authors.forename: J H Frederik
authors.initials: JH
authors.lastname: Falkenburg
authors.forename: Nancy
authors.initials: N
authors.lastname: Hardy
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kroeger
authors.forename: Jose
authors.initials: J
authors.lastname: Leis
authors.forename: John
authors.initials: J
authors.lastname: Levine
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Karl
authors.initials: K
authors.lastname: Peggs
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
authors.forename: Alan S
authors.initials: AS
authors.lastname: Wayne
authors.forename: Sergio
authors.initials: S
authors.lastname: Giralt
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
authors.forename: Koen
authors.initials: K
authors.lastname: van Besien
mesh_terms: D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D017710:Lymphocyte Transfusion; D008228:Lymphoma, Non-Hodgkin; D009101:Multiple Myeloma / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012008:Recurrence; D014184:Transplantation, Homologous; D017211:Treatment Failure